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ABSTRACT
It has long been promised that dendritic cell immunotherapy would revolutionize the treatment of neoplastic
disease. Now, more than 10 years since the publication of the first clinical data, a firmer understanding of
immunology and dendritic cell biology is beginning to produce interesting clinical results. This article reviews
the clinical trials that established many of the concepts with which today’s investigators are achieving improved
results, discusses issues in dendritic cell immunotherapy that are currently unresolved, and offers a perspective
on the strategies that the authors believe will be important for the design of future vaccine trials, including the
use of Toll-like receptor agonists as maturation agents, the accessory use of the plasmacytoid dendritic cell
subset, and the maximization of T-cell help.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
In the 10 years that have elapsed since the publica-
ion of the ﬁrst dendritic cell (DC) immunotherapy trial
1], progress has been made toward the goal of using
Cs as a legitimate therapy for the treatment of neo-
lastic disease. This painstaking progress has been based
omewhat on empirical trial and error but also on im-
ortant advances in basic immunology and DC biology
hat have provided a fundamental understanding of the
ellular and molecular interactions that govern adaptive
mmune responses. As newly established concepts are
ollectively accepted and assimilated, reports of efﬁcacy
ecome more common and, importantly, become
ncreasingly accompanied by immune correlates
hat can validate bona ﬁde vaccine responses. We
egin with a discussion of issues important to the
eneration of effective DC vaccines and a summary
f signiﬁcant or insightful trials that have used this
pproach. This discourse is followed by the authors’
erspective on the promising strategies that may
roduce meaningful clinical results in the future. t
B&MTYELOID VERSUS PLASMACYTOID LINEAGES
In vivo, there exist 2 subpopulations of DCs that
eem to derive independently frommyeloid or lymphoid
ommitted precursors [2-4]. DCs that express myeloid-
peciﬁc lineage markers, also known as DC1, seem to be
est suited for the generation of antigen-speciﬁc effector
cells and are the subset that has been used exclusively
n published vaccine trials [2-4]. DCs that express lym-
hoid-speciﬁc lineage markers, called plasmacytoid
Cs or DC2, may serve as accessory cells that aid in
he immune response by secreting large amounts of
ype I interferons (IFNs; eg, IFN-) in response to
iral infection and other types of inﬂammation
2-7]. As the principal component of DC vaccines,
yeloid DCs have been extensively characterized
nd reviewed [4,8,9]. Figure 1 summarizes the life
ycle of a myeloid DC from generation in the bone
arrow to immature immune sentinel in the periph-
ry to mature mediator of T-cell responses in the
ymph node. Figure 2 outlines major differences be-
ween the myeloid and plasmacytoid subsets.
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1Consistent with an apparent role in viral defense,
lasmacytoid DCs express intracellular Toll-like re-
eptors (TLR)–7 and -9, which are important in the
ecognition of microbial nucleic acids [2,3,6,10], but
o not express other TLRs, such as TLR-1, -2, -3, -4,
5, or -8 [2,3]. In general, plasmacytoid DCs do not
xpress high levels of major histocompatibility com-
lex (MHC) class II [2,11-13], do not have the phago-
ytic capacity of their myeloid counterparts [2,13], do
ot present antigens particularly well [2,14], and are
oor T-cell stimulators [2,3]. Unlike myeloid DCs,
hich begin life in circulation but typically migrate to
eripheral tissues as they differentiate, fully differen-
iated plasmacytoid DCs may circulate in the blood,
here they comprise approximately 0.1% of circulat-
ng white cells [3,15], and can be identiﬁed as rare
D4/CD3 cells that also express CD123 and
igure 1. The life cycle of a myeloid (DC1) dendritic cell (DC). Im
re taken up by scavenger receptors or by macropinocytosis (a). N
resentation, DCs are unique in that exogenous antigens may acce
nﬂammatory agents induce the migration of the immature dendriti
rocess (c) is controlled by different subsets of chemokine recepto
xtracellular matrix. T-cell activation units (d), consisting of pept
isplayed after maturation on the DC, where they may constitu
hemokines and cytokines, whose activity is modulated by protease
ajor histocompatibility complex; MIIC, MHC class II compartmen
rom Hartgers et al. [9] with permission.LA-DR [2,3,5,16]. In response to activation by TLR d
14igation, inﬂammatory chemokines, or both, plasma-
ytoid DCs migrate to lymphoid organs or to sites of
nﬂammation, where they can secrete up to 10 pg of
FN- per cell in situ [2-4,7,17,18].
It is interesting to note that upon activation,
lasmacytoid DCs may adopt the characteristics of
heir myeloid counterparts, including upregulation of
HC class II and costimulatory molecules, interleu-
in (IL)–12 secretion, effective antigen presentation,
nd the ability to stimulate antigen-speciﬁc T lym-
hocytes [2-4,13,19,20]. Such reports have somewhat
bfuscated the issue of whether the myeloid and plas-
acytoid DC phenotypes represent true lineage spec-
ﬁcity or, despite lineage speciﬁc marker expression,
ctually represent different stages of maturation or
evelopment among a single committed population
2,3]. Moreover, though the preponderance of evi-
DCs are very efﬁcient in antigen uptake and processing. Antigens
the common pathways for MHC class I and II–restricted antigen
lass I pathway (b). This process is referred to as cross-presentation.
nto the T-cell areas of secondary lymphoid organs. This migratory
is aided by the secretion of metalloproteases, which degrade the
ded MHC class II and co-stimulatory molecules such as B7, are
of the immunologic synapse. Mature DCs also secrete several
rotease inhibitors (e). ER indicates endoplasmic reticulum; MHC,
, transporter associated with antigen processing. Figure reproducedmature
ext to
ss the c
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Bity, some reports suggest that plasmacytoid DCs,
oth mature and immature, may instead promote tol-
rance and immune suppression [21-24].
In a clinical setting, plasmacytoid DCs may be
nnecessary components of a myeloid-based vaccine
hat can use the patient’s own plasmacytoid subset in
ivo. These in situ plasmacytoid DCs might require
ctivation via the application of inﬂammatory cyto-
ines or TLR-7/TLR-9 agonists (eg, unmethylated
pG dinucleotides) [10]. Alternatively, contaminating
lasmacytoid DCs in a vaccine preparation could be
reactivated by the inﬂammatory cytokines used in
aturation, thereby abrogating the need for the gen-
igure 2. Subsets of human dendritic cells (DCs). Blood DCs,
obilized by Flt-3 ligand, contain both CD11c myeloid DCs
MDCs) and CD11c plasmacytoid DCs (PDCs). Most clinical
tudies to date have been performed with DCs made by culturing
onocytes with GM-CSF and IL-4. These preparations contain
ells that resemble interstitial DCs and are devoid of Langerhans
ells. These DCs are immature and require exogenous factors for
aturation. Myeloid DCs can also be generated by culturing
D34 hematopoietic precursor cells (HPCs) with GM-CSF and
NF-, thus allowing the derivation of each myeloid DC subset. A
istinct subset of precursors, CD34CD45RA, gives rise in vitro
o plasmacytoid DCs upon culture with Flt-3 ligand. Figure repro-
uced from Banchereau et al. [8] with permission.ration of systemic inﬂammation. Although contami- (
B&MTating plasmacytoid DCs might be found in myeloid
reparations derived from adherence or elutriation
rocedures, it is expected that they would be absent in
reparations derived from CD14 monocyte selec-
ion. Maintenance of such contaminating populations
ight also have to be supported by the addition of
lt-3 ligand. Adding to this set of unknown variables,
he degree by which plasmacytoid DC participation
ight enhance adaptive immune responses has not yet
een determined; ie, such participation might not nec-
ssarily impart a critical level of immune enhancement
n vivo, thus allowing the contribution of the plasma-
ytoid subset to be ignored in the context of the
yeloid-dependent response. Therefore, it remains to
e determined whether the optimal generation or per-
etuation of an adaptive immune response will require
he participation of accessory plasmacytoid DCs in
upport of antigen-loaded myeloid DCs (Figure 3).
ENERATION PROTOCOLS
Most clinical protocols have generated myeloid
Cs by the adherence of peripheral blood mononu-
lear cells (PBMCs) to tissue culture plasticware and
ubsequent incubation in a cytokine cocktail contain-
ng granulocyte-macrophage colony-stimulating fac-
or (GM-CSF) and IL-4, as ﬁrst reported by Sallusto
nd Lanzavecchia in 1994 [25] and later modiﬁed by
omani et al. in 1996 [26] and Heiser et al. in 2000
27]. There are, however, many other methods by
hich myeloid DCs may be generated for vaccine
herapy, and it is not known whether any of these
lternative methods imparts a degree of clinical efﬁ-
acy superior to that of the standard approach. Few
rotocols have deviated from the simple formula of
ifferentiating adherent monocytes with GM-CSF
nd IL-4. Some trials that have experimented with the
tandard protocol are listed in Table 1. Myeloid DCs
ay be generated from either monocytic CD14 pre-
ursors or CD34 hematopoietic progenitor cells
28,29]. Although monocytes may be collected in far
reater numbers, progenitor cells maintain the ability to
ivide and may be expanded exponentially in culture. Of
recent studies that used CD34 progenitors, 1 dem-
nstrated remarkable efﬁcacy [30], whereas the other 2
id not [31,32]; however, the studies differed in many
ther aspects, and any meaningful comparison of a
ingle variable would be difﬁcult.
After activation of DC precursors by GM-CSF,
C differentiation may be inﬂuenced by a variety of
ytokines, including IL-4 [4,33], IL-15 [4,34], tumor
ecrosis factor (TNF)– [4,35], IFN- [4,36-38], and
hymic stromal lymphopoietin [4,39]. Some preclini-
al studies have indicated that DCs generated with
L-15 are highly efﬁcient in cytotoxic T lymphocyte
CTL) priming [4,34], and DCs generated with thy-
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1ic stromal lymphopoietin elicit mainly an allergic-
ype (T-helper type 2 [Th-2]) response [4,39]; how-
ver, the vast majority of published clinical trials have
sed GM-CSF for activation and either IL-4 or
NF- as the agent of differentiation. Coculture with
igure 3. Loading and presentation of MHC class I and MHC clas
hagocytosed or taken up by receptor-mediated endocytosis. Onc
ompartment, loaded onto empty MHC class II molecules, and pre
left). Dendritic cells also possess the ability to present some exogen
echanism termed cross-presentation. Internal dendritic cell antigens,
nfection, are constitutively degraded at a basal level by the protea
oaded onto MHC class I, and transported to the cell surface for prim
accines with peptides, the peptide antigens are thought to mainly b
eing internally processed by the dendritic cell. MHC indicates ma
ransporter associated with antigen processing.
able 1. Clinical Trials That Have Generated Immature Dendritic Ce
n GM-CSF and IL-4
Reference
Source of Precursor
Cells
Length of
Incubation
anchereau [30] CD34 selection of
mobilized PBMCs
8 d
arrou [42] Culture of total
PBMCs followed by
elutriation for DC
purification
7 d
edrosian [85] Elutriation of
neutrophil-depleted
PBMCs
36 h
i Nicola [32] CD34 selection of
mobilized PBMCs
12 d
ackensen [31] CD34 selection of
mobilized PBMCs
7 d for expansio
then 21 d for
differentiation
tift [63] CD14 selection of
PBMCs
5 d
tift [64] CD14 selection of
PBMCs
5 dC, subcutaneously; SCF, stem cell factor.
16L-4 generates a homogenous population of immature
yeloid DCs that most resemble interstitial DCs,
hereas coculture with TNF- yields a heteroge-
eous population of interstitial DCs and Langerhans
ells that exhibit a mature phenotype [4,35]. From a
tigens by dendritic cells. Antigens external to the dendritic cell are
nalized, these exogenous antigens are degraded in the lysosomal
on the cell surface, where they may prime a cognate CD4 T cell
derived class II antigens on MHC class I by a poorly characterized
s those present endogenously or, eg, by mRNA transfection or viral
egradation products are processed in the endoplasmic reticulum,
cognate CD8 T cells (right). During the loading of dendritic cell
pty MHC class I and class II molecules on the cell surface without
ocompatibility complex; MIIC, MHC class II compartment; TAP,
ethods Other Than the Incubation of Adherent Monocytes
Cytokine Cocktail
Direct
Generation of
Mature DCs?
Clinical
Responses
M-CSF, Flt-3L, TNF- Yes 41% (7/17)
M-CSF, IL-13 No 0% (0/24)
M-CSF, calcium
ionophore A23187, IL-2,
IL-12
Yes 0% IV (0/8)
10% ID (1/10)
22% IN (2/9)
M-CSF, TNF-, SCF,
Flt-3L
Yes 17% (1/6)
L-3, IL-6, SCF for
expansion, then
GM-CSF, IL-4
No 14% (2/14)
M-CSF, IL-4  patients
received low-dose IL-2
SC for 12 d after DC
administration
No 0% (0/20)
M-CSF, IL-4  6 patients
received IFN- 12 h
before DC
administration
No 40% (4/10)s II an
e inter
sented
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Dendritic Cell Clinical Trials
Bunctional standpoint, it will likely be difﬁcult to de-
ermine with certainty the full relevance of these dif-
erent DC subsets to the generation of an optimal
mmune response in vivo.
There has been much interest in the potential of
he partially mature DCs that may be generated by
ulturing adherent PBMCs in GM-CSF and IFN-
or 3 days [4,36-38], although this strategy has been
eported only preclinically in the literature. Biologi-
ally, it is unclear at what stage DC function might be
est inﬂuenced by IFN-. In vivo, immature myeloid
Cs might come into contact with IFN-–secreting
lasmacytoid DCs just before maturation near sites of
nﬂammation. In such instances, IFN-might serve as
signal for maturation and migration to the peripheral
ymphoid organs. Alternatively, myeloid DCs might en-
ounter the plasmacytoid subset after maturation near
he high endothelial venules of the peripheral lymphoid
rgans [2,3]. In either case, plasmacytoid DCs might
e providing additional cytomodulatory signals, in-
luding signals that require cell-to-cell contact, that
an modify the myeloid subset or naive T lymphocytes
n a functional manner that ampliﬁes speciﬁc antiviral
esponses.
NTIGENIC PREPARATION AND DC LOADING
A wide variety of antigens and antigenic prepara-
ions (Table 2) have been used to load DCs or other-
ise elicit an immune response. The strategies for
enerating an antigen-speciﬁc immune response in-
lude the loading of DCs with single antigens in the
orm of tumor-speciﬁc peptides [1,40,41], proteins
42] (including idiotype protein for immunotherapy
f myeloma [43-45]), and single messenger RNA
mRNA) transcripts [46,47], as well as attempts to
xpress tumor antigens endogenously in DCs by the
se of plasmid or viral constructs [32]. In contrast to a
otal antigen approach, the single-antigen approach is
able 2. Approaches to Loading Dendritic Cell Vaccines and the Associa
References Loading Approach
Singl
A
, 40, 41 Peptide Si
2 Whole protein Si
3-45, 121-123 Idiotype Si
6, 47 mRNA Si
2 Viral vector Si
0, 31, 52-56 Peptide mix M
7-67 Tumor lysate M
8, 69 Tumor mRNA M
0 Whole tumor cells M
2 Tumor heat shock proteins M
3 Tumor dendritic cell fusion M
otal
R indicates complete response.peciﬁc and avoids the theoretical problem of priming D
B&MTn autoimmune response against normal cellular an-
igens. Moreover, single-antigen or single-epitope im-
une responses are easier to document and quantify,
articularly by staining of antigen-speciﬁc T cells with
LA-/peptide-speciﬁc tetramers. On the downside,
ingle-antigen/-epitope approaches suffer from a va-
iety of deﬁciencies, including tumor immune escape,
LA speciﬁcity (in the case of peptides), and a lack of
-cell help via the failure to load either MHC class II
peptides and mRNA) or MHC class I (protein) with
matched or linked epitope [48-51]. Most impor-
antly, the single-antigen approach does not allow the
mmune system to choose the epitopes from the total
ntigen pool that will be most useful for the promul-
ation of an effective response. It should be recog-
ized that the most effective epitopes will vary from
atient to patient according to HLA type, genetic
ackground, and the antigen pool of each individual
umor.
Many different trials have also used a multiple-
ntigen approach, including the use of peptide mixes
30,31,52-56], whole tumor lysates [57-67], total tu-
or mRNA [68,69], whole tumor cells [70], tumor
poptotic bodies [71], tumor-derived heat shock pro-
eins [72], and tumor/DC fusions [73]. In addition, 2
rials, currently under way, use unloaded DCs derived
rom leukemic blasts [74] (G. Ossenkoppele, personal
ommunication, Vrije University Medical Center,
005), a strategy originally described by Choudhury et
l. [75] and modiﬁed subsequently by Westers et al.
76] and Houtenbos et al. [77]. Most of these strate-
ies can theoretically present a full complement of
umor-speciﬁc antigens to the patient’s immune sys-
em, yet all suffer from a common shortcoming.
hese strategies have the potential to load either
HC class I (tumor mRNA, cell fusions, and leuke-
ia-derived DCs) or MHC class II (tumor lysates,
umor cells, tumor apoptotic bodies, and heat shock
rotein preparations), but not both. When loading
bined Clinical Efﬁcacy of Selected Studies
ple No. of
Studies
Any Clinical
Response Durable CR
3 3.1% (1/32) 3.1% (1/32)
1 0.0% (0/24) 0.0% (0/24)
6 22.9% (11/48) 6.3% (3/48)
2 0.0% (0/19) 0.0% (0/19)
1 16.6% (1/6) 16.6% (1/6)
7 21.7% (25/115) 5.2% (6/115)
11 12.9% (18/140) 2.1% (3/140)
2 5.6% (1/18) 0.0% (0/18)
1 31.6% (6/19) 15.8% (3/19)
1 6.7% (1/15) 0.0% (0/15)
1 8.7% (2/23) 0.0% (0/23)
36 14.4% (66/459) 3.7% (17/459)ted Com
e/Multi
ntigen
ngle
ngle
ngle
ngle
ngle
ultiple
ultiple
ultiple
ultiple
ultiple
ultipleCs by phagocytosis, investigators typically cite the
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1henomenon of cross-presentation as a mechanism by
hich both MHC class II and MHC class I may be
oaded (Table 3). Cross-presentation is a bona ﬁde
iological phenomenon by which MHC class II anti-
ens are also presented by MHC class I; however,
everal recent reports have demonstrated suboptimal
fﬁciency of cross-presentation in vivo, and some in-
estigators now question its physiologic relevance [78-
0]. To generate an optimal immune response, we
ould hypothesize that both MHC class I and MHC
lass II should be efﬁciently loaded with tumor-spe-
iﬁc antigens, because this approach might lead to a
aximization of T-cell help in support of all relevant
D8 effectors. To address recent questions about
he efﬁciency of cross-presentation, we have com-
ared the T cell–stimulatory abilities of DCs loaded
ith either class I or class II antigens with those of
Cs doubly loaded with both class I and class II
ntigens. Our preliminary data support the contention
hat cross-presentation can be suboptimal in its efﬁ-
iency (unpublished data).
ATURATION PROTOCOLS
The manner by which a DC vaccine is matured is
ikely to be of critical importance in the generation of
obust, antigen-speciﬁc immune responses. Most pub-
ished trials that have used matured DCs cite the use
f TNF- or ITIP (a combination of the inﬂamma-
ory cytokines IL-1, TNF-, IL-6, and the CCR7-
nducing steroid compound prostaglandin E2) as the
gent of maturation. One of the most widely used
aturation cocktails is ITIP [81-83]. Other immuno-
odulatory or inﬂammatory agents that have been
sed either clinically or preclinically include CD40
igand (CD40L) [84], IFN- [36-38], IFN-, Ca2
onophore, IL-2, IL-12 [85], and TLR agonists [86].
ach of these compounds has its own unique and
seful biological effects, and if improvements to the
urrent gold standard are to be forthcoming, such
mprovements will likely be generated by a cocktail
pproach rather than the use of a single agent. Prom-
sing maturation molecules include CD40L and TLR
able 3. Studies in Which Clinical Outcome Can Be Signiﬁcantly Corr
Reference Disease
Clinical
Response
anchereau [30] Melanoma 7/17 Integrated direct
indexed score,
utterfield [40] Melanoma 1/13 Demonstrated th
vastly higher in
amanaka [62] Glioblastoma 2/10 2/2 responders we
DTH positive
u [65] Glioblastoma 3/9 3/3 patients alive
secreting tumo
1/6 nonrespondTH indicates delayed-type hypersensitivity.
18gonists. CD40L can upregulate DC immunocompe-
ence by mimicking the effects of T-cell help, and the
se of CD40L as a single agent of DC maturation has
een cited clinically (D. Gabrilovich, personal com-
unication, University of South Florida, H. Lee Mof-
tt Cancer Center, 2003). TLRs recognize nonspe-
iﬁc pathogen–associated molecular patterns such as
ipopolysaccharide, double-stranded RNA, or un-
ethylated CpG dinucleotides, and TLR agonism can
romote DC maturation in the absence of other in-
ammatory agents [86]. We have demonstrated that
he addition of the synthetic RNA analogue and TLR
gonist poly I:C to the ITIP cocktail in vitro leads to
n impressive upregulation of DC IL-12 secretion
unpublished data). Similarly, Cisco et al. [87] have
emonstrated that transfection of DCs with mRNA
ncoding a constitutively active TLR-4 allows the
eneration of antigen-speciﬁc CTL activity superior
o that of DCs matured with either ITIP or lipopoly-
accharide. Although highly promising, these types of
trategies have, as yet, been described only preclini-
ally.
Of note, Bedrosian et al. [85] used a unique mat-
ration cocktail of Ca2 ionophore, IL-2, and IL-12
o generate mature DCs. Although the use of Ca2
onophore to rapidly generate mature DCs from pe-
ipheral blood monocytes was originally reported by
zerniecki et al. [88] in 1997, this strategy does not
ften appear in the clinical literature. It is likely that
dditional agents such as Ca2 ionophore, CD40L, or
LR agonists will eventually become more common-
lace in the clinical literature, perhaps in conjunction
ith ITIP, as investigators seek to improve current
rotocols by generating in vitro–derived mature DCs
hat more closely rival the functional efﬁcacy of their
n vivo–derived counterparts.
OUTE OF DC ADMINISTRATION
During the normal processes of immune ho-
eostasis, the immature DC maintains itself in pe-
ipheral tissues, where it constantly samples the anti-
enic milieu of its surroundings. Upon detection of a
ith Antigen-Speciﬁc Immunologic Phenomena
Immune Correlate
call responses of 4 peptide antigens (8 total assays) to obtain an
orrelated with clinical outcome (P < .015)
– and IL-4–secreting CD3/MART-1 tetramer cells were
responders than among all other nonresponders
H positive to tumor lysate, but only 1/4 nonresponders was
0 wk after vaccination exhibited significantly increased IFN-–
en–specific (by tetramer staining) T cells after vaccination. Only
ibited a similar phenomenonelated w
and re
which c
at IFN-
single
re DT
at >20
r antig
ers exh
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Bdanger” signal, such as a TLR agonist or an inﬂam-
atory cytokine, the DC matures, upregulates CCR7,
nd migrates to the T-cell areas of the peripheral
ymphoid organs—the sites at which T-cell priming
ill occur [80,89,90]. However, an oft-cited study by
e Vries et al. [83] demonstrated that migration of
ature, in vitro–derived human DCs to peripheral
ymphoid organs is of dubious efﬁciency, on the order
f only 1% to 4% (but this rate is statistically better
han the 0.3% migration rate observed with immature
Cs). These data were later corroborated by Ridolﬁ
t al. [91], who produced essentially identical results in
trial that involved 8 cancer patients. Lending cre-
ence to the hypothesis that in vitro–derived DCs
igrate suboptimally in vivo, Bedrosian et al. [85]
emonstrated superior peptide-speciﬁc delayed-type
ypersensitivity and IFN- responses when mature
Cs were administered intranodally in comparison to
ntradermally (90% of vaccinees intranodally versus
0% of vaccinees intradermally). This same study also
emonstrated that immune responses were virtually
bsent when DCs were delivered intravenously [85].
ost recent studies cite intranodal administration as
he delivery method of choice, and this cumbersome
rocedure will likely remain necessary until such time
hat in vitro–derived DCs can be induced to migrate
n a more efﬁcient manner.
MMUNOMONITORING
A key issue facing DC immunotherapy has been
he inconsistent ability of investigators to correlate
accine-speciﬁc or antigen-speciﬁc immune responses
ith clinical observations. Frequently, a delayed-
ype hypersensitivity response may be weakly corre-
ated with efﬁcacy [61,92], but too often it is reported
hat antigen-speciﬁc assays such as ELISpot (Enzyme-
inked Immunospot), proliferation, or CTL lysis
annot be correlated with clinical observations
40,42,58,60,63,92]. Conversely, some investigators
ave demonstrated a good correlation between im-
une responses and clinical remissions. Some of the
rials discussed subsequently are well known precisely
ecause clinical and immunologic data are well corre-
ated (Table 3); however, oncology still lacks a break-
hrough trial with wholly unambiguous correlations,
uch as the recent publication of Lu et al. [93], which
orrelated the reduction of human immunodeﬁciency
irus (HIV) viral loads with HIV-speciﬁc T-cell re-
ponses in patients receiving DC immunotherapy for
hronic HIV infection.
LINICAL TRIALS
In 1995, Mukherji et al. [1] published the results of
he ﬁrst clinical trial that sought to establish the fea- r
B&MTibility and safety of MAGE-1 peptide–loaded HLA-
1 DCs for the treatment of metastatic melanoma.
fter this preliminary report, 3 high-proﬁle publica-
ions demonstrated that DC immunotherapy could
nduce objective clinical responses as well.
Hsu et al. [43] claimed a clinical response rate of
5% (2 complete responses [CRs] and 1 partial re-
ponse [PR] out of 4 patients) after the intravenous
dministration of blood-isolated, idiotype-pulsed DCs
o patients with follicular B-cell lymphoma. Patients
lso received subcutaneous injections of soluble idio-
ype.
After a successful phase I trial, Tjoa et al. [52]
emonstrated a clinical response rate of 27% (9 PRs
ut of 33 patients) after the intravenous administra-
ion of prostate-speciﬁc membrane antigen (PSMA)
eptide–pulsed immature DCs to patients with meta-
tatic prostate cancer. DCs in this study were gener-
ted by the culture of adherent PBMCs in GM-CSF
nd IL-4.
Nestle et al. [94] cited a 38% clinical response rate
2 CRs, 3 PRs, and 1 minor response (MR) out of 16
atients) after the intranodal administration of peptide
MART-1, tyrosinase, and glycoprotein [gp]100 or
AGE-1 and MAGE-3, depending on patient HLA
ype) or lysate-pulsed immature DCs to patients with
etastatic melanoma. As with Tjoa et al., DCs were
enerated by culture of adherent PBMCs in GM-CSF
nd IL-4.
Despite these apparent successes, many basic
uestions about the underlying biology of human DCs
ere poorly understood and still remain to be an-
wered in vivo. In 1999 and 2001, Dhodapkar et al.
ublished 2 important studies demonstrating that DC
aturation was required for the induction of antigen-
peciﬁc immune responses by the administration of
oth mature [95] and immature [96] DCs to healthy
olunteers. Most importantly, they demonstrated that
he administration of immature DCs could result in
he development of antigen-speciﬁc tolerance [96].
our years later, these observations were underscored
n a review article that cited a 14.9% (21/141) clinical
esponse rate to immature vaccines and a 22.8% (18/
9) response rate to mature vaccines [92]. Other re-
iews on this topic were also published contempora-
eously [97].
At the same time, Mackensen et al. [98] and Morse
t al. [99] demonstrated that either immature or ma-
ure DCs injected intravenously localized initially to
he lungs and subsequently to liver, spleen, and bone
arrow, with no evidence of lymph node localization.
hese authors further demonstrated that matured
Cs injected intralymphatically could localize to re-
ional lymph nodes for at least 24 hours, and imma-
ure DCs administered subcutaneously remained es-
entially in situ with very low levels of migration to
egional lymph nodes (0.1%-0.4%, in agreement with
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1e Vries et al. [83]). Fong et al. [100] would later
emonstrate a lack of antigen-speciﬁc Th-1 responses
n prostate cancer patients receiving antigen-pulsed
Cs intravenously, but not intradermally or intralym-
hatically. Given this new understanding of human
C biology, it might be tempting to view the results
f previous studies in a somewhat ambiguous manner,
nd this issue warrants further discussion.
Immature DC vaccines are not completely with-
ut beneﬁcial therapeutic effects [92], and it is gener-
lly assumed that some differential level of maturity
ay be imparted to human DCs simply by routine
andling and culture, as is commonly observed with
ouse Langerhans cells after short-term culture
101,102]. This simple assumption helps to mitigate
he major criticism of Nestle et al. [94] and of Tjoa et
l. [52]. Although it is more difﬁcult to reconcile Tjoa
nd associates’ intravenous vaccination schedule with
linical efﬁcacy, it is not entirely without precedent. In
he pivotal study of Fong et al. [100], 55% of patients
ho received intravenous administration of DCs de-
eloped antigen-speciﬁc antibody titers typical of a
h-2 type response. Therefore, in pretreated prostate
ancer patients with minimal residual disease, it is not
ifﬁcult to envision transient tumor susceptibility to
SMA antibodies in much the same way that circulating
ymphomas may be susceptible to rituximab (Rituxan
enentech, Inc, San Francisco, CA) [103] and that solid
reast tumors may be susceptible to trastuzumab (Her-
eptin Genentech, Inc, San Francisco, CA) [104]. The
uccess reported by Hsu et al. [43] is tempered some-
hat by the study’s small sample size and by a per-
eived difﬁculty in separating immune responses due
o DC vaccination and immune responses due to the
dministration of soluble idiotype protein. Neverthe-
ess, the efﬁcacy of this approach continued to be
xcellent in a larger follow-up study by Timmerman
t al. [44], and it seems likely that some unique fea-
ures of B-cell lymphomas or of this particular vacci-
ation approach are contributing to clinical success in
manner not entirely analogous to that with other
C-based therapeutic strategies.
In 2001, Banchereau et al. [30] published a land-
ark study against which future studies will be com-
ared. In this trial, CD34 progenitor-derived DCs
ulsed with 4 HLA-A2 melanoma peptides (MART-1,
yrosinase, MAGE-3, and gp100) were delivered sub-
utaneously to 18 patients with stage IV metastatic
elanoma. The vaccine induced antigen-speciﬁc
FN- secretion in response to at least 1 of the 4
eptides in 17 of the 18 patients, as assayed by ELIS-
ot. In general, the number of antigens to which the
atient responded and the magnitude of each response
orrelated well with the overall clinical outcome. In
ddition to excellent immune correlates, the trial pro-
uced impressive clinical results, with 3 CRs and 4 o
20Rs out of 17 evaluable patients (41%). The durability
f these remissions, however, was not discussed.
The following year, Heiser et al. [46] pursued a
ovel strategy in the generation of a DC vaccine for
rostate cancer. DCs derived by the incubation of ad-
erent PBMCs in GM-CSF and IL-4 were coincubated
ith in vitro–derived prostate-speciﬁc antigen (PSA)
RNA. DCs were then cultured overnight to allow
xpression, processing, and presentation of the PSA an-
igen, as well as, the authors claim, slight maturation by
nonspeciﬁc, mRNA-dependent mechanism. The vac-
ine was delivered both intravenously and intradermally
o 13 patients with metastatic prostate cancer. Strik-
ngly, in all 8 patients evaluated by ELISpot and all 10
atients evaluated by chromium 51 release cytotoxic-
ty, responses against PSA were signiﬁcantly higher
fter vaccination. Unfortunately, clinical results were
ifﬁcult to assess and were not durable. As many
nvestigators have noted [47,105,106], transfection of
Cs with mRNA alone does not allow for robust
riming of CD4 lymphocytes, thus leading to a re-
ponse that is largely devoid of T-cell help.
Very recently, Su et al. [47] implemented an ele-
ant strategy designed to address the lack of T-cell
elp that plagues mRNA-based trials. After the gen-
ration of DCs by the incubation of adherent mono-
ytes in GM-CSF and IL-4, the authors electropo-
ated the DCs with a human telomerase reverse
ranscriptase (hTRT) lysosome-associated membrane
rotein fusion mRNA. hTRT encodes for the cata-
ytic subunit of human telomerase, an antigen prefer-
ntially expressed in most tumors. To allow presenta-
ion of hTRT epitopes by MHC class II for the
eneration of antigen-speciﬁc CD4 T cells, the
TRT transcript was fused to the lysosomal targeting
ignal of lysosome-associated membrane protein 1.
fter electroporation, the DCs were matured with
TIP and delivered intradermally to patients with
etastatic prostate cancer. In comparison to patients
hose DC vaccine was transfected with the native
TRT transcript, those who received the fusion tran-
cript demonstrated an 8-fold increase in hTRT-spe-
iﬁc CD4 lymphocytes after vaccination, as assayed
y IFN- ELISpot. It is interesting to note that up-
egulation of hTRT-speciﬁc CD4 lymphocytes did
ot seem to alter the quantity or quality of hTRT-
peciﬁc CD8 lymphocytes; moreover, impressive
linical responses were not observed.
By using a unique method of total antigen loading,
’Rourke et al. [70] reported improved efﬁcacy for the
reatment of metastatic melanoma by using a DC vac-
ine that was loaded with whole, irradiated tumor cells.
fter maturation by culture in monocyte-conditioned
edium and intradermal administration, O’Rourke
t al. reported a clinical response rate of 32% (6/19),
ncluding 3 durable CRs that involved the resolution
f lesions in lymph node, kidney, adrenal gland, me-
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Biastinum, pleuropericardium, and lung. The authors
ere also able to correlate clinical success with disease
urden, demonstrating that 5 of 6 clinical responders
ntered the study with serum S-100B levels of 0.36
g/mL, whereas only 2 of 8 nonresponders entered
he study with S-100B levels below this threshold.
Yu et al. [65] attempted to address central nervous
ystem immunoprivilege by the generation of a vac-
ine for malignant glioblastoma multiforme. DCs
ere generated by the incubation of adherent PBMCs
n GM-CSF and IL-4 and then loaded by overnight
ncubation with autologous tumor lysate and injected
ubcutaneously. Although antigen-speciﬁc immune
esponses were difﬁcult to evaluate, the authors did
emonstrate the expansion of IFN-–secreting HER-2
c-erb-b2)–speciﬁc CD8T cells in 3 patients, as well as
xpansion of IFN-–secreting CD8T cells speciﬁc for
different glioblastoma-associated antigens in a single
atient (HER-2, gp100, and MAGE-1) by tetramer
nalysis. In 2 patients who underwent craniotomy dur-
ng the study, the authors also reported T-cell inﬁl-
rates composed of both CD4 and CD8 lympho-
ytes. Most impressive was the study’s reported
edian survival of 133 weeks (versus 30 weeks for
ited historical controls and perhaps 65 weeks under
he best of circumstances [107]); moreover, 3 (38%) of
patients were alive at 200 weeks after vaccination.
ll 3 surviving patients had signiﬁcantly expanded
FN-–secreting, tetramer-speciﬁc T-cell populations
fter vaccination, whereas only 1 of 6 patients who did
ot survive demonstrated a similar expansion. The
mall sample size, however, precludes deﬁnitive anal-
sis of efﬁcacy.
Despite the selected reports of clinical efﬁcacy
escribed previously, most DC immunotherapy trials
ave not reported signiﬁcant clinical responses. Of 98
rials published through mid 2003, only 17 trials doc-
mented a complete remission. These 17 trials shared
o common characteristic that separated them from
rials without a CR, and the combined rate of CR was
nly 12% (33 CRs out of 273 patients vaccinated)
108]; moreover, clinical responses were rarely dura-
le, and relapse was commonplace. Our own analysis
f 36 recent trials (Table 2) suggests even more pes-
imistic results. Because of this suboptimal clinical
icture, investigators continue to look for new strate-
ies that can increase the efﬁcacy of DC vaccination.
ne of the most relevant “new” strategies has been
ocumented for nearly 25 years [48-51]: the optimal
eneration of T-cell help.
HE IMPORTANCE OF T-CELL HELP
N THE GENERATION AND PERPETUATION
F THE ADAPTIVE IMMUNE RESPONSE
To appreciate the importance of T-cell help in the
ctivation of the adaptive immune response, it is im- n
B&MTortant to consider the sequence of events that occur
n its absence. Upon detection of a “danger” signal,
Cs in vivo can efﬁciently coordinate the elimination
f cells presenting foreign antigens by the priming of
D8 effectors that recognize such antigens. Equally
s important, in the absence of danger signals, DCs
aintain self-reactive T cells in a state of nonrespon-
iveness. Although T-cell precursors that recognize
elf-antigens with high afﬁnity are deleted during de-
elopment in the thymus as part of the process of
entral tolerance, medium- and low-afﬁnity self-reac-
ive CD8 T-cell precursors are normally maintained
n an unresponsive state by the mechanisms of periph-
ral tolerance. Effective priming of circulating CD8
cells not only requires DC presentation of the
ognate peptide antigen in the context of MHC class
, but also requires CD4 T-cell help [109,110]. Pos-
ible mechanisms of T-cell help include the upregulation
f costimulatory molecules on the antigen-presenting
ell (APC) surface after CD40/CD40L signaling be-
ween the helper T cell and the APC [106,111-113].
ther investigators, however, have reported the tran-
ient expression of CD40 on the surface of CD8
TLs and suggest that T-cell help involves direct
ignaling between the CD4 cell and the CD8 cell.
n the latter model, the APC assumes the additional
unction of bringing CD4 and CD8 cells into close
roximity for proper cross talk to occur [114-116].
CD4 helper T cells are generated, not by anti-
ens endogenous to the APC, but by exogenous anti-
ens that are engulfed by APCs and presented on the
urface by the MHC class II complex. In the absence
f appropriate T-cell help, activated CD8 clones
end to become lethargic and may not respond to
uture activation stimuli [109,117,118]. This is one of
everal mechanisms by which the immune system is
revented from recognizing self antigens and inducing
n autoimmune response [119].
Our data have indicated that the double loading of
C MHC class I and MHC class II positively affects
rimary and recall T-cell responses through the max-
mization of CD40L-mediated T-cell help. In addi-
ion to describing this phenomenon empirically, we
rovide preliminary evidence to suggest it mechanis-
ically [120], and we are optimistic that continued
ocus on this aspect of immune stimulation could
esult in the development of DC vaccines with signif-
cantly enhanced efﬁcacy.
ONBIOLOGICAL IMPEDIMENTS TO SUCCESS:
OST AND REGULATORY OVERSIGHT
In addition to the biological impediments that
ave hindered a wider implementation of DC immu-
otherapy, regulatory oversight and cost now add ad-
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1itional levels of complexity to a treatment that may
e only marginally effective in a select population of
ndividuals. These costs include many thousands of
ollars for patient apheresis, monocyte enrichment,
he expensive cytokines and growth media required to
enerate and mature DCs, and (optionally) various
eans of vaccine administration. Labor costs and the
xpense of maintaining a Food and Drug Administra-
ion (FDA)–compliant current Good Manufacturing
ractice (cGMP) facility for complex DC manipula-
ions can be substantial. Investigators working with an
stablished cGMP facility might expect to incur costs
f $4,000 to $16 000 per patient, depending on a
road host of variables. Investigators seeking to estab-
ish and maintain their own FDA-compliant facility
hould expect costs to be appreciably greater.
Even though most DC immunotherapy trials are
hase I in scope, regulatory requirements have be-
ome considerable. Similar regulatory oversight is re-
uired in Canada, Europe, Australia, and many other
ountries where clinical cellular therapy trials are be-
ng conducted. This process requires approval of the
linical protocol and validated cell-manufacturing
rocedures by the FDA or equivalent state-recognized
egulatory agency. The use of clinical-grade reagents
s always most desirable. If such reagents are not
vailable, procurement of certiﬁcates of analysis to
ocument the sterility of the major reagents is re-
uired. The costs and regulatory requirements of cur-
ent DC studies underscore the importance of con-
ucting well-designed trials with evaluable clinical and
aboratory end points so that maximal information can
e obtained from each study.
ONCLUSION
Despite a persistent lack of consensus in almost
very important aspect of DC immunotherapy, a mo-
icum of progress has been achieved over the last 10
ears. Many investigators now accept that DCs must
e matured and must reach the T-cell areas of the
eripheral lymphoid organs to function as advertised.
n the coming years, we are optimistic that investiga-
ors will begin to embrace other important concepts,
uch as the use of TLR agonists in the maturation
rocess, the loading of vaccines with multiple anti-
ens, and the maximization of T-cell help. Also, with
ontinued empirical progress, it seems plausible that
C immunotherapy may one day provide realistic
reatment opportunities for distinct subsets of patients
ith neoplastic disease. Moreover, despite the slow
rogress and, at times, ambiguous results, those in the
eld continue to remain highly committed to the
evelopment of therapeutic strategies that will be of
eneﬁt to broader cross-sections of individuals as well.
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